For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts

Blog
FDA can’t stomach fluoride and doesn’t want you to, either
On May 13, the Food and Drug Administration (FDA) announced that it would begin a process intended to exclude ingestible prescription fluoride products for…

Blog
Free the Economy podcast: Drug costs and benefits with Sally Pipes
In this week’s episode we cover reforms to the Endangered Species Act, attacks on US tech firms, nuclear power innovation,…

Blog
The MAHA Report is a missed opportunity
Less than six months into the new administration, the Department of Health and Human Services (HHS) has produced its Make Our Children Healthy Again…
Search Posts
Blog
GOP proposal includes reductions in health care expenditures
Over the weekend the House Committee on Energy and Commerce released a proposal describing how it would achieve the expenditure goals for the Reconciliation…
Blog
The numbers don’t add up in new Medicaid paper
In a recently released working paper, authors Angela Wyse and Bruce D. Meyer purport to show that the ACA Medicaid expansion saved 27,400 lives…
Letters
CEI joins ATR Coalition Urging CRA on Medical Debt Rule
Dear Member of Congress, We are writing to express our concerns regarding the Consumer Financial Protection Bureau’s finalized rule on eliminating medical debt records from…
Blog
FTC’s second interim report on PBMs: Don’t hold your breath
The Federal Trade Commission (FTC) will consider issuing a second interim report on Pharmacy Benefit Managers (PBMs) tomorrow during its January 14 open meeting.
Blog
Congress shouldn’t rely on incomplete FTC PBM study
Lawmakers are making a last-minute push to regulate the practices of pharmacy benefit managers (PBMs) during the lame duck session. However, it would be a…
Wall Street Journal
A Thumb on the Scale for Wegovy
The Biden administration announced one more bit of executive overreach on its way out the door. On Nov. 26, the Centers for Medicare and Medicaid…